Simultaneous glutamine metabolism and PD-L1 inhibition to enhance suppression of triple-negative breast cancer

Simultaneous glutamine metabolism and PD-L1 inhibition to enhance suppression of triple-negative breast cancer

Blockade of programmed cell death 1 ligand (PD-L1) has been used to treat triple-negative breast cancer (TNBC), and various strategies are under investigation to improve the treatment response rate. Inhibition of glutamine metabolism can reduce the massive consumption of glutamine by tumor cells and...

Full description

Bibliographic Details
Main Authors: Hu, Y. (Author), Li, Y. (Author), Shi, H. (Author), Tang, Y. (Author), Wang, S. (Author), Xu, Z. (Author), Yuan, C. (Author), Zhang, J. (Author)
Format: Article
Language:English
Published: BioMed Central Ltd 2022
Subjects:
Amino acids
Anti-PDL1
Antitumor effect
Biocompatibility
Cell death
Diseases
Glutamine metabolism inhibitor
Interstitial fluids
Layered semiconductors
Mammals
Metabolism
Molybdenum compounds
MoS2 nanosheet
MoS2 nanosheets
Programmed cell deaths
Response rate
Sulfur compounds
T-cells
Treatment response
Triple-negative breast cancer
Triple-negative breast cancers
Tumors
Tumour cells
Urea
V9302
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items